Boston, MA, 04/07/2014 (usastockreports) – Is this the do or die situation for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), after falling consecutively for the second time to get its ‘808 Patent’ on Copaxone®. The PTO or U.S Patent and Trademark Office declared that the reissue of the ‘808 Patent’ was called off, as the patent was found invalid by the Federal Circuit’s Court of Appeal on July, 2013.
However, in spite of the rejection declaration on the reissue of the ‘808 Patent’ application for the second time, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has raised voice against Federal Circuit’s improper decision. They have moved Supreme Court on the basis of the biased decision of PTO. It states that the patent was declared invalid improperly because of indefiniteness.
‘After reaction’ on the decision:
The U.S. Supreme Court has made some positive action on behalf of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to uphold some Copaxone® patents. This news created an unbelievable relief to the company’s stock, which shot up by 6.86% and stuck at $52.84 on that very day. The company can get back to a wealthy situation, if the ‘808 Patent’ claim goes in favor of the company.
Looking forward for an expected right on Copaxone® patent, the Pharmaceutical Company here waits to regain its patent and serve thousands of customers globally. The hot topic surrounding the company now is whether the U.S. PTO’s rejection or reissue of ‘808 Patent’, which among these is going to steal the show?